Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte is set to dominate the pneumococcal vaccine market with its best-in-class next-gen PCV, and current clinical data and trial designs support this outlook. The company also has a diverse pipeline with potential in other disease indications. Although facing standard risks in the biotech industry, Vaxcyte's financials and product potential position it as a strong investment opportunity.

Bears say

Vaxcyte is a clinical-stage company with a promising product pipeline in development, however, it is still several years away from bringing a product to market. Additionally, while the recent expansion of the adult vaccination market is a positive development, competitors such as SP0202 from Sanofi may pose a threat in the future. The current valuation of the company is attractive, but may already be pricing in success for the Ph3 readout for VAX-31, limiting potential price appreciation for investors. Additionally, there may be some uncertainty surrounding the outcome of the VAX-31 Ph2 infant trial, which could impact investor confidence.

Vaxcyte (PCVX) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Buy based on their latest research and market trends.

According to 4 analysts, Vaxcyte (PCVX) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.